A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• BRCA1 is crucial for DNA repair and genomic stability.
• BRCA1 expression is hormone-dependent in breast cells and affects response to endocrine therapy.
• Defects in BRCA1 pathway influence sensitivity to DNA damaging agents and chemotherapy.

Purpose of the Study:

• To investigate the role of BRCA1 in DNA repair and its implications for breast cancer treatment.
• To evaluate the efficacy of platinum-based drugs and PARP inhibitors in BRCA1-defective breast cancers.
• To explore the response of triple-negative breast cancer (TNBC) to cisplatin in relation to BRCA1 function.

Main Methods:

• Review of preclinical and clinical studies on BRCA1 mutations in breast cancer.
• Analysis of BRCA1's role in response to ERα antagonists like fulvestrant.
• Assessment of cisplatin efficacy in neoadjuvant and adjuvant settings for BRCA1-mutated and TNBC.

Main Results:

• Wild-type BRCA1 is necessary for inhibiting breast tumor cell growth with fulvestrant.
• Loss of BRCA1 function leads to resistance against ERα antagonists.
• Neoadjuvant cisplatin demonstrates high pathological response rates in BRCA1-mutated breast cancer, especially TNBC.

Conclusions:

• BRCA1 status is a predictive biomarker for response to DNA damaging agents and endocrine therapy.
• Platinum-based drugs, including cisplatin, are effective against hereditary breast cancers with BRCA1 defects.
• TNBC may possess a dysfunctional BRCA1 repair pathway, explaining its heightened sensitivity to cisplatin.